Disclaimer:  VFC has no affiliation with Cel-Sci Corp or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.  

Cel-Sci Corp (CVM):  Cel-Sci is a perfect example of a company that has gone through its highs and lows while being highly tradable along the way.  Now, tho, the story is a bit different as we are in the Endgame for the long-ongoing worldwide trial investigating the effectiveness of lead product candidate Multikine in the treatment of head and neck cancer.  We've already re-hashed what Multikine is and what it may be able to do in previous blog postings, but a couple of things have changed the last time I wrote.  Most notably, the Russell. 

It was announced earlier this month that CVM met the criteria for inclusion into the Russell 3000 and Russell 2000 indexes.  Inclusion commences on 1 July, with the final day of "reconstitution" falling on 28 June - the final trading day of the month.  It is expected to be one of the highest trading days of the year, according to the Internet (Russell website) and historical trends.  This is huge for CVM, as shares will be picked up and traded in various funds that track the broad stock market.  It also lends an heir of credibility to an otherwise little-known small cap that doesn't seem to be on the radar of main street...

Click below, after the ad, for full article.

Enjoy spending those trading gains on cheap flights from CheapOair!

Great prices, especially for international travel! Click below for the savings!

Soak Up the Sun and the Savings! Save up to $18 off flights & hotels with promo code BEACH18 Book Now!

Read more


Disclaimer:  VFC has no affiliation with Cel-Sci Corp or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.  

Cel-Sci Corp (CVM):  Is the short attack over?  

The ever-so-volatile shares of Cel-Sci - which ran from under $3 to over $8 in just a few months earlier this year - are back to trading in the mid-$4 range after a recent short attack killed the rally.  Interestingly, the attack was swift and quickly drove the share price down, whereas sometimes these things are a little more gradual and protracted over time.  Part of the reason for the quick action may be due to the timeline (or lack of a definitive timeline) relating to the Phase III Multikine trial.  Previous estimations have noted that the trial would be complete in the first half of 2019, and if that is still the case, then news could come at any time.  That would drive those on the short side to want to act quickly, or start covering, as it would be dangerous to be short - should the results come in positive.  Should they be negative, tho, it would be a bad day for longs...

Read more